Orlando, USA (19 – 23 October 2019) – Xavant Technology (Pty) Ltd will be exhibiting at the American Society of Anesthesiologists at the Orange County Convention Center in Orlando, USA from 19 to 23 October 2019. The company is expected to announce an important product update at the meeting while showcasing their latest objective NMT…
The Stimpod NMS450X+, equipped with two different modalities (AMG and EMG), empowers anaesthesiologists to achieve safer intraoperative control of patients’ neuromuscular blockade. The full case NMT Monitoring enables safe extubation and eliminate residual paralysis in any hospital setting, provider preference and surgery type. This advanced technology empowers clinicians to have a safer and more precise control over the neuromuscular blockade during surgery, aligning with the latest guideline-concordant recommendations for the monitoring of patients for residual paralysis following the administration of a neuromuscular reversal agent. The ASA and ESAIC strongly recommend the use of a quantitative neuromuscular blocking agent monitor in conjunction with neuromuscular blocking agents.
While reversal drugs like Sugammadex are commonly used for NMBA reversal, they are not a foolproof solution and residual paralysis remains a significant concern based on clinical evidence. By incorporating the Stimpod NMS450X+ into their practice, anaesthesiologists can proactively monitor the depth of neuromuscular blockade, significantly reducing the incidence of residual paralysis in patients. This contributes to improved patient outcomes and a safer post-operative recovery.
The Stimpod NMS450X+ offers a cost-effective solution in the OR, PACU and ICU. With its two modalities, AMG and EMG, the device provides flexibility in monitoring options. The only neuromuscular monitoring system available with both AMG and EMG enabling cost control at the point-of-care based on need and specific setting, allowing affordable standardisation across the entire hospital. Cost of Care model, enabling monitoring of all drug usage to ensure optimal use, thus saving on both paralytic and recovery agents. This cost-saving feature ensures efficient resource management without compromising patient safety.
AMG offers the most cost-effective option to implement with a reusable sensor and versatile patient setup options enabling neuromuscular transmission monitoring of the hand, toe or face.
EMG is ideally suited for neuromuscular monitoring of surgeries where tucked hands and arms are required, with optimised performance through a patented, skin-like electrode.
Residual neuromuscular blockade after anaesthesia has been linked to severe complications and adverse outcomes, including increased oxygen desaturation, postoperative pneumonia, airway obstruction, and reintubation. By utilizing the Stimpod NMS450X+ and effectively preventing residual NMB, clinicians can contribute to reduced LOS in hospitals and improve patient recovery rates.
Anaesthesiologists worldwide who have adopted the Stimpod NMS450X+ demonstrate their commitment to following the latest guidelines and best practices in anaesthesia. By incorporating a quantitative NMBA monitor into their practice, clinicians align themselves with the recommendations set forth by the ASA and ESAIC, promoting a higher standard of care and patient safety. By utilizing the Stimpod NMS450X+, anaesthesiologists are a testament to its effectiveness to improve patients outcomes and can contribute to the reduction of adverse events and enhance the recovery process for their patients.
